Oncology

Multi-Gene Assays Now Recommended To Refine Chemotherapy Decisions in Breast Cancer

April 15, 2009
Kathy S Albain MD

Kathy S Albain MD

11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews Kathy Albain, Professor of Medicine at Loyola University, Chicago, on her return from the 2009 St Gallen consensus meeting which formulated updated recommendations about adjuvant therapy for breast cancer. The 21 gene recurrence score and the 70-gene profiling assay have now been endorsed by this Swiss meeting as significant contributors to the decision making process on cytotoxic chemotherapy for patients with estrogen receptor positive disease, including both node negative and node positive early breast cancer.

Download this interview

Add podcast to iTunes

Similar Interviews

  • Audio Journal of Oncology 14.1, February 2006

    • Reporting from: - San Antonio Breast Cancer Symposium 2005 In this edition: The targeted drug trastuzumab may be used in place of anthracyclines

  • Early Breast Cancer Chemotherapy: Long Term Findings

    • Richard Peto REFERENCE: Lancet 371:29-40; January 5, 2008 RICHARD PETO, Oxford University The prospect of

  • Non-Anthracyline Regimen May Be O.K. for Patients with Early Breast Cancer taking Trastuzumab (Herceptin)

    • Dennis Slamon, UCLA School of Medicine, Los Angeles It may be reasonable to replace the anthracycline component of adjuvant chemotherapy with

    Post a comment